quinazolines has been researched along with 6-methyl-2-(phenylethynyl)pyridine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bertorelli, R; Forlani, A; Fredduzzi, S; Grilli, M; Grzelak, ME; Guthrie, DH; Higgins, GA; Hodgson, RA; Hunter, JC; Lu, SX; Nicolussi, E; Parker, EM; Pond, AJ; Reggiani, A; Varty, GB | 1 |
| Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Morin, N; Morissette, M | 1 |
2 other study(ies) available for quinazolines and 6-methyl-2-(phenylethynyl)pyridine
| Article | Year |
|---|---|
The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: a comparison of efficacy and side-effect profiles.
Topics: Analgesics; Animals; Anti-Anxiety Agents; Body Temperature; Conditioning, Psychological; Excitatory Amino Acid Antagonists; Male; Mice; Motor Activity; Pyridines; Quinazolines; Rats; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Thiazoles | 2005 |
Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
Topics: 2-Amino-5-phosphonovalerate; Amino Acids; Animals; Basal Ganglia; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Imidazoles; Levodopa; Macaca fascicularis; Oximes; Parkinsonian Disorders; Phenols; Piperidines; Pyridines; Quinazolines; Radioligand Assay; Receptor, Metabotropic Glutamate 5; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Tritium; Xanthenes | 2013 |